Saturday 17 October 2026
Export RDY’s income statement to Excel — free account
Dr. Reddy's Laboratories Ltd
RDY Healthcare Drug Manufacturers Specialty & Generic
Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025. In the quarter to June 2026, revenue fell 14.4%, EPS fell 70.0%, free cash flow fell 143.4% and total debt rose 34.0%, each against the same quarter a year earlier.
13.05
0.15
+1.16%
Follow RDY
| Mar '17 | Mar '18 | Mar '19 | Mar '20 | Mar '21 | Mar '22 | Mar '23 | Mar '24 | Mar '25 | Mar '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 5 | 8 | 7 | 5 | 6 | 8 | 6 | 2 | 4 |
P/E ratio |
36.83 | 35.22 | 25.19 | 24.60 | 43.04 | 29.88 | 17.10 | 18.30 | 19.98 | 25.79 |
Altman Z-Score |
4.33 | 3.86 | 5.35 | 6.30 | 7.07 | 6.38 | 7.87 | 8.43 | 5.94 | 5.26 |
P/S ratio |
3.08 | 2.46 | 3.02 | 2.89 | 3.93 | 3.27 | 3.16 | 3.67 | 2.88 | 3.22 |
Altman Z″-Score (non-manufacturers) |
3.84 | 4.50 | 5.81 | 6.70 | 6.32 | 6.56 | 8.51 | 8.73 | 6.93 | 6.10 |
P/FCF ratio |
0.00 | 49.30 | 20.76 | 20.90 | 32.12 | 56.74 | 19.42 | 53.50 | 69.98 | 53.62 |
P/Operating CF |
47.79 | 63.22 | 67.96 | 477.74 | 66.55 | 80.42 | 39.07 | 89.82 | 42.42 | 77.38 |
Beneish M-Score |
(2.46) | (2.62) | (2.73) | (2.56) | (2.78) | (2.38) | (2.68) | (2.25) | (1.97) | (2.59) |
Dividend Safety Score |
— | — | — | — | — | — | — | — | — | 74 |
P/B ratio |
3.50 | 2.76 | 3.32 | 3.25 | 4.30 | 3.68 | 3.36 | 3.66 | 2.78 | 2.84 |
Price to Tangible BV |
5.76 | 4.49 | 5.07 | 4.09 | 5.60 | 4.42 | 3.97 | 4.28 | 4.11 | 4.12 |
EV/Sales |
3.30 | 2.67 | 3.11 | 2.86 | 3.90 | 3.21 | 2.96 | 3.45 | 2.85 | 3.19 |
EV/EBITDA |
18.76 | 16.05 | 14.48 | 11.04 | 16.20 | 16.67 | 10.43 | 11.68 | 10.41 | 15.04 |
EV/Operating CF |
21.58 | 21.03 | 16.67 | 16.73 | 20.71 | 24.55 | 12.36 | 21.22 | 19.91 | 18.81 |
EV/FCF |
(23.96) | 53.45 | 21.36 | 20.70 | 31.88 | 55.73 | 18.18 | 50.29 | 69.10 | 53.09 |
Quick Ratio |
0.66 | 0.89 | 1.09 | 1.06 | 1.03 | 1.20 | 1.58 | 1.69 | 1.14 | 1.13 |
Current Ratio |
1.18 | 1.57 | 1.92 | 1.79 | 1.78 | 1.93 | 2.41 | 2.58 | 1.92 | 1.80 |
Net Debt/EBITDA |
1.24 | 1.25 | 0.40 | (0.10) | (0.12) | (0.30) | (0.71) | (0.75) | (0.13) | (0.15) |
Debt/Assets |
22.36% | 22.45% | 17.03% | 9.51% | 11.40% | 11.55% | 4.19% | 5.18% | 9.48% | 13.34% |
Debt/Equity |
0.40 | 0.40 | 0.27 | 0.14 | 0.18 | 0.18 | 0.06 | 0.07 | 0.14 | 0.20 |
Asset Turnover |
0.67 | 0.64 | 0.66 | 0.73 | 0.77 | 0.75 | 0.77 | 0.78 | 0.73 | 0.60 |
Operating CF/Net income |
1.78 | 1.83 | 1.53 | 1.53 | 2.07 | 1.19 | 1.31 | 0.82 | 0.82 | 1.33 |
Capex/Depreciation |
(3.63) | (0.93) | (0.52) | (0.46) | (0.98) | (1.33) | (1.49) | (1.77) | (1.94) | (1.78) |
Interest Coverage |
17.33 | 14.08 | 17.76 | 33.46 | 34.54 | 29.92 | 40.88 | 38.67 | 25.52 | 13.48 |
| 9.66% | 7.83% | 13.70% | 12.69% | 10.68% | 12.76% | 20.60% | 21.63% | 18.13% | 11.40% | |
| 5.70% | 4.41% | 8.09% | 8.17% | 7.03% | 8.30% | 14.09% | 15.60% | 12.72% | 7.63% | |
ROIC |
5.45% | 4.78% | 8.51% | 13.64% | 12.25% | 10.36% | 19.68% | 19.31% | 13.82% | 8.55% |
Return on Tangible Assets |
16.64% | 10.05% | 17.27% | 17.78% | 14.15% | 15.73% | 24.00% | 24.32% | 26.05% | 17.09% |
Average Days of Receivables |
98.69 | 104.43 | 94.49 | 105.12 | 95.54 | 113.66 | 107.60 | 104.92 | 101.33 | 110.01 |
Research and Development Expense of Revenue |
13.86% | 12.88% | 10.16% | 8.81% | 8.71% | 8.14% | 7.89% | 8.18% | 8.40% | 7.15% |
Selling, General and Administrative Expense of Revenue |
32.93% | 33.01% | 31.78% | 28.71% | 28.80% | 28.95% | 27.67% | 27.64% | 28.84% | 31.76% |
Intangible Assets out of Total Assets |
0.22 | 0.22 | 0.21 | 0.14 | 0.15 | 0.11 | 0.11 | 0.11 | 0.22 | 0.20 |
Share Based Compensation of Revenue |
0.28% | 0.32% | 0.27% | 0.30% | 0.31% | 0.28% | 0.17% | 0.15% | 0.13% | 0.08% |
Graham Net Nets |
0.01 | 0.03 | 0.06 | 0.11 | 0.07 | 0.11 | 0.15 | 0.14 | 0.10 | 0.10 |
Graham Number |
3.35 | 3.12 | 4.21 | 4.28 | 4.28 | 5.04 | 7.12 | 8.58 | 8.39 | 7.67 |
Earnings Yield |
2.71% | 2.84% | 3.97% | 4.06% | 2.32% | 3.35% | 5.85% | 5.46% | 5.00% | 3.88% |
Free Cash Flow Yield |
(4.47%) | 2.03% | 4.82% | 4.78% | 3.11% | 1.76% | 5.15% | 1.87% | 1.43% | 1.86% |
Revenue per Share |
2.61 | 2.63 | 2.68 | 2.79 | 3.13 | 3.41 | 3.60 | 4.03 | 4.58 | 4.30 |
Operating CF per Share |
0.40 | 0.33 | 0.50 | 0.48 | 0.59 | 0.45 | 0.86 | 0.66 | 0.65 | 0.73 |
Capex per Share |
(0.76) | (0.20) | (0.11) | (0.09) | (0.21) | (0.25) | (0.28) | (0.38) | (0.47) | (0.47) |
Free Cash Flow per Share |
(0.36) | 0.13 | 0.39 | 0.39 | 0.38 | 0.20 | 0.59 | 0.28 | 0.19 | 0.26 |
Cash per Share |
0.34 | 0.39 | 0.44 | 0.43 | 0.59 | 0.74 | 0.92 | 1.18 | 0.82 | 1.13 |
Shareholders Equity per Share |
2.30 | 2.34 | 2.44 | 2.48 | 2.85 | 3.03 | 3.38 | 4.05 | 4.74 | 4.87 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.30 | 2.34 | 2.44 | 2.48 | 2.85 | 3.03 | 3.38 | 4.05 | 4.74 | 4.87 |
Free Cash Flow |
(299.00) | 109.00 | 324.00 | 320.00 | 317.00 | 163.00 | 487.00 | 230.00 | 157.00 | 215.00 |
Working Capital |
237.00 | 614.00 | 793.00 | 763.00 | 887.00 | 1,158.00 | 1,474.00 | 1,824.00 | 1,401.00 | 1,432.00 |
Capital Expenditures |
(631.00) | (168.00) | (91.00) | (76.00) | (171.00) | (207.00) | (229.00) | (315.00) | (388.00) | (392.00) |
Net Current Asset Value |
71.00 | 161.00 | 424.00 | 704.00 | 763.00 | 1,049.00 | 1,412.00 | 1,692.00 | 1,103.00 | 1,098.00 |
EV/EBIT |
34.45 | 31.84 | 22.91 | 15.23 | 22.51 | 23.35 | 12.74 | 14.24 | 12.88 | 21.18 |
Capex to Sales |
0.29 | 0.08 | 0.04 | 0.03 | 0.07 | 0.07 | 0.08 | 0.09 | 0.10 | 0.11 |
Price to Operating Income |
32.17 | 29.36 | 22.28 | 15.38 | 22.68 | 23.77 | 13.61 | 15.15 | 13.05 | 21.39 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.20 | 0.20 | 0.23 | 0.24 | 0.22 | 0.19 | 0.19 | 0.19 | 0.17 | 0.18 |
Cash ROIC |
(10.12%) | 3.58% | 11.00% | 11.83% | 9.69% | 4.57% | 13.02% | 5.02% | 3.03% | 3.70% |
Accounts Receivable Turnover |
3.59 | 3.60 | 3.71 | 3.73 | 3.85 | 3.63 | 3.40 | 3.63 | 3.77 | 3.35 |
Accounts Payable Turnover |
4.90 | 4.44 | 4.46 | 4.96 | 4.34 | 4.00 | 3.93 | 4.00 | 4.01 | 4.38 |
Inventory Turnover |
2.33 | 2.28 | 2.18 | 2.25 | 2.18 | 2.05 | 2.05 | 2.05 | 1.98 | 2.05 |
Average Days of Payables |
78.46 | 89.35 | 75.29 | 75.46 | 100.11 | 92.83 | 90.69 | 97.63 | 96.27 | 76.84 |
Days of Inventory on Hand |
166.77 | 161.70 | 174.25 | 158.77 | 191.28 | 184.84 | 166.73 | 200.79 | 192.08 | 176.13 |
Average Receivables |
605.00 | 605.50 | 600.00 | 621.50 | 673.00 | 779.50 | 881.00 | 922.50 | 1,010.50 | 1,068.50 |
Average Payables |
196.50 | 227.00 | 228.50 | 215.50 | 273.00 | 331.00 | 329.50 | 346.50 | 394.00 | 386.50 |
Average Inventory |
413.00 | 443.50 | 466.50 | 475.50 | 543.00 | 646.00 | 631.50 | 677.50 | 797.50 | 824.00 |
Average Assets |
3,262.00 | 3,427.50 | 3,362.00 | 3,170.00 | 3,355.50 | 3,745.00 | 3,888.00 | 4,283.00 | 5,211.00 | 5,973.50 |
Average Common Equity |
1,925.00 | 1,928.00 | 1,985.00 | 2,040.50 | 2,210.50 | 2,438.00 | 2,660.50 | 3,088.50 | 3,656.50 | 4,000.50 |
Columns are period end dates